Erratum to “Efficacy of Adjunctive Tofacitinib Therapy in Mouse Models of Tuberculosis” [EBioMedicine 2 (8), August 2015, 868–873]

On page 867, third paragraph of the Introduction Section, the following sentence, “In efforts to block pro-inflammatory responses, we recently showed that tofacitinib, a Janus kinase (JAK) inhibitor that was FDA-approved in 2012 for treating rheumatoid arthritis and ulcerative colitis (Traynor, 2012; Sandborn et al., 2012), blocked immune containment and promoted bacterial replication during chronic TB in the mouse paucibacillary model in the absence of anti-TB drugs (Maiga et al., 2012)”. Should read: “In efforts to block pro-inflammatory responses, we recently showed that tofacitinib, a Janus kinase (JAK) inhibitor that was FDA-approved in 2012 for treating rheumatoid arthritis (Traynor, 2012), and shown to induce clinical response and remission in patients with ulcerative colitis (Sandborn et al., 2012), blocked immune containment and promoted bacterial replication during chronic TB in the mouse paucibacillary model in the absence of anti-TB drugs (Maiga et al., 2012)”. We regret the error.